Fresenius Medical Care (NYSE:FMS - Get Free Report) is scheduled to post its quarterly earnings results before the market opens on Tuesday, November 5th. Analysts expect Fresenius Medical Care to post earnings of $0.42 per share for the quarter.
Fresenius Medical Care (NYSE:FMS - Get Free Report) last released its quarterly earnings results on Tuesday, July 30th. The company reported $0.38 EPS for the quarter, hitting the consensus estimate of $0.38. The business had revenue of $5.13 billion during the quarter, compared to analyst estimates of $5.28 billion. Fresenius Medical Care had a net margin of 2.72% and a return on equity of 5.48%. On average, analysts expect Fresenius Medical Care to post $2 EPS for the current fiscal year and $2 EPS for the next fiscal year.
Fresenius Medical Care Stock Performance
Shares of Fresenius Medical Care stock traded down $0.47 during trading on Tuesday, hitting $20.39. 517,377 shares of the stock were exchanged, compared to its average volume of 367,969. The stock's fifty day moving average is $20.31 and its 200 day moving average is $20.18. The stock has a market cap of $11.97 billion, a PE ratio of 22.91, a P/E/G ratio of 1.11 and a beta of 0.91. The company has a debt-to-equity ratio of 0.45, a quick ratio of 1.09 and a current ratio of 1.46. Fresenius Medical Care has a 12 month low of $16.46 and a 12 month high of $22.76.
Analysts Set New Price Targets
Several equities research analysts recently weighed in on FMS shares. StockNews.com started coverage on shares of Fresenius Medical Care in a report on Tuesday, October 8th. They issued a "strong-buy" rating for the company. Truist Financial upped their price objective on shares of Fresenius Medical Care from $22.00 to $23.00 and gave the stock a "hold" rating in a report on Monday, October 7th. One research analyst has rated the stock with a sell rating, two have given a hold rating, one has given a buy rating and one has issued a strong buy rating to the company. According to MarketBeat.com, the company currently has a consensus rating of "Hold" and a consensus target price of $23.00.
View Our Latest Stock Report on Fresenius Medical Care
About Fresenius Medical Care
(
Get Free Report)
Fresenius Medical Care AG provides dialysis and related services for individuals with renal diseases in Germany, North America, and internationally. The company offers dialysis treatment and related laboratory and diagnostic services through a network of outpatient dialysis clinics; materials, training, and patient support services comprising clinical monitoring, follow-up assistance, and arranging for delivery of the supplies to the patient's residence; and dialysis services under contract to hospitals in the United States for the hospitalized end-stage renal disease (ESRD) patients and for patients suffering from acute kidney failure.
Further Reading
Before you consider Fresenius Medical Care, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Fresenius Medical Care wasn't on the list.
While Fresenius Medical Care currently has a "Hold" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
With average gains of 150% since the start of 2023, now is the time to give these stocks a look and pump up your 2024 portfolio.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
